Futuristic Products Company established a stock appreciation rights (SARS) program which entitles its new president Jill...

Transcribed Image Text:

Futuristic Products Company established a stock appreciation rights (SARS) program which entitles its new president Jill Castleberry to receive cash for the difference between the market price of the stock and a preestablished price of S30 a share on 20,000 shares. The date of grant is December 31, 2014 and requires the president remain in her position during 2015, 2016 and 2017. As of January 1, 2018, the SARS are exercisable for 5 years before they lapse. Jill exercises the SARS on January 2, 2020. The company has adopted the fair value method of expensing its SARS to employees and it has run the Black-Scholes pricing model for them. The company controller has also updated the pricing model through the date that the SARS were exercised. The "total" fair value (i.e., the preestablished price has not been deducted yet) for all SARS per the original run of the model (and the updated runs) are shown below. ngatwe Date Estimated Total Fair Value of SARS /per share 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 21/31/2019 $30 36 39 45 36 48 48 1/2/2020 A. Prepare a Schedule of Compensation Expense pertaining to the SARS for the period 2015- 2020. B. Prepare the journal entry for compensation expense in 2014, 2018, and 2019. Futuristic Products Company established a stock appreciation rights (SARS) program which entitles its new president Jill Castleberry to receive cash for the difference between the market price of the stock and a preestablished price of S30 a share on 20,000 shares. The date of grant is December 31, 2014 and requires the president remain in her position during 2015, 2016 and 2017. As of January 1, 2018, the SARS are exercisable for 5 years before they lapse. Jill exercises the SARS on January 2, 2020. The company has adopted the fair value method of expensing its SARS to employees and it has run the Black-Scholes pricing model for them. The company controller has also updated the pricing model through the date that the SARS were exercised. The "total" fair value (i.e., the preestablished price has not been deducted yet) for all SARS per the original run of the model (and the updated runs) are shown below. ngatwe Date Estimated Total Fair Value of SARS /per share 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 21/31/2019 $30 36 39 45 36 48 48 1/2/2020 A. Prepare a Schedule of Compensation Expense pertaining to the SARS for the period 2015- 2020. B. Prepare the journal entry for compensation expense in 2014, 2018, and 2019.